Presidio’s HCV program targets the HCV NS5A protein and is well positioned to compete in the HCV therapy market. Presidio’s pan-genotypic HCV NS5A inhibitor, ravidasvir hydrochloride (formerly known as PPI-668), has completed Phase 1 clinical studies in both healthy volunteers and HCV patients, where it exhibited potent antiviral activity, enhanced PK properties and an excellent safety/tolerance profile. A Phase 2a 12-week combination study in HCV 1a patients that included the protease inhibitor, faldaprevir (BI201335), and the non-nucleoside inhibitor, deleobuvir (BI207127), with or without ribavirin was completed in 1Q14 and demonstrated SVR24 in 92% of patients treated in RBV-containing arms and 86% in the overall trial population. Three patients in the trial attained SVR24 after only 8 weeks of therapy, of which two patients did not receive ribavirin.
Presidio has an extensive intellectual property portfolio for ravidasvir hydrochloride (formerly known as PPI-668).
Presidio Pharmaceuticals 